BC
BMY icon

Birchview Capital’s Bristol-Myers Squibb BMY Stock Holding History

Birchview Capital’s Portfolio BMY Stock Details BMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$17.1M Sell
297,243
-9,025
-3% -$518K 8.01% 2
2026
Q1 		$18.6M Buy
306,268
+3,426
+1% +$200K 10.57% 2
2025
Q4 		$16.3M Sell
302,842
-14,000
-4% -$674K 9.56% 2
2025
Q3 		$14.3M Sell
316,842
-6,516
-2% -$304K 10.79% 2
2025
Q2 		$15M Sell
323,358
-361,834
-53% -$17.8M 14.86% 1
2025
Q1 		$41.8M Buy
685,192
+10
+0% +$583 36.29% 1
2024
Q4 		$38.8M Sell
685,182
-1,000
-0.1% -$55.9K 31.53% 1
2024
Q3 		$35.5M Sell
686,182
-2,036
-0.3% -$95.5K 30.74% 1
2024
Q2 		$28.6M Sell
688,218
-15,388
-2% -$689K 26.42% 1
2024
Q1 		$38.2M Buy
703,606
+1,308
+0.2% +$66.6K 31.1% 1
2023
Q4 		$36M Sell
702,298
-13,999
-2% -$735K 28.19% 1
2023
Q3 		$41.6M Sell
716,297
-12,288
-2% -$753K 35.32% 1
2023
Q2 		$46.6M Hold
728,585
– – 34.92% 1
2023
Q1 		$50.5M Buy
728,585
+800
+0.1% +$56.4K 39.54% 1
2022
Q4 		$52.4M Hold
727,785
– – 36.99% 1
2022
Q3 		$51.7M Hold
727,785
– – 36.43% 1
2022
Q2 		$56M Sell
727,785
-26,321
-3% -$2M 40.76% 1
2022
Q1 		$55.1M Sell
754,106
-12,000
-2% -$806K 39.65% 1
2021
Q4 		$47.8M Sell
766,106
-30,000
-4% -$1.76M 30.8% 1
2021
Q3 		$47.1M Hold
796,106
– – 32.05% 1
2021
Q2 		$53.2M Buy
796,106
+1,920
+0.2% +$125K 31.82% 1
2021
Q1 		$50.1M Sell
794,186
-200
-0% -$12.4K 29.76% 1
2020
Q4 		$49.3M Hold
794,386
– – 28.39% 1
2020
Q3 		$47.9M Buy
794,386
+2,000
+0.3% +$120K 32% 1
2020
Q2 		$46.6M Buy
792,386
+6,601
+0.8% +$395K 28.16% 1
2020
Q1 		$43.8M Buy
785,785
+7,200
+0.9% +$440K 38.85% 1
2019
Q4 		$50M Buy
778,585
+731,585
+1,557% +$41.9M 36.33% 1
2019
Q3 		$2.38M Buy
47,000
+3,000
+7% +$141K 1.59% 7
2019
Q2 		$2M Buy
44,000
+24,000
+120% +$1.12M 1.21% 8
2019
Q1 		$954K Buy
+20,000
New +$996K 0.6% 16

Other funds holding BMY

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Birchview Capital's BMY Position: Q2 2026 in Review

Birchview Capital reduced its Bristol-Myers Squibb (BMY) stake by 2.9% in Q2 2026, selling an estimated $518K and leaving 297,243 shares worth $17.1M. The position accounts for 8.01% of the portfolio, ranked #2.

Birchview Capital first reported a position in BMY in Q1 2019 and has held it in 30 quarters since. The position peaked at $56M in Q2 2022. 2,517 funds tracked by Wall St. Rank hold BMY as of Q2 2026.

  • Birchview Capital held 297,243 shares of Bristol-Myers Squibb worth $17.1M as of Q2 2026.
  • Birchview Capital sold 9,025 Bristol-Myers Squibb shares in Q2 2026, an estimated $518K.
  • Bristol-Myers Squibb made up 8.01% of Birchview Capital's portfolio in Q2 2026, its #2 holding.
  • Birchview Capital first reported a position in Bristol-Myers Squibb in Q1 2019 and has held it in 30 quarters since.
  • Birchview Capital's Bristol-Myers Squibb position peaked at $56M in Q2 2022.
  • 2,517 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.

Based on Birchview Capital's 13F filing for Q2 2026, filed 14 Aug 2026.